By Colin Kellaher

Pfizer Inc. and OPKO Health Inc. on Monday said the U.S. Food and Drug Administration accepted for review their application for somatrogon, a once-weekly human-growth hormone for pediatric patients with growth-hormone deficiency.

The companies said the agency set a target action date in October for somatrogon, which, if approved, would help reduce the burden of daily growth-hormone injections.

New York drug maker Pfizer and OPKO, a Miami healthcare-services company, signed a worldwide agreement in 2014 to develop and commercialize somatrogon for growth-hormone deficiency.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 04, 2021 08:54 ET (13:54 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Opko Health Charts.
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Opko Health Charts.